Salil Srivastava, Ph.D.

Salil Srivastava is a research product team lead in the Research and Early Development Cardiovascular, Renal, and Immunology (RED CVRI) division at Bayer, and a member of the Precision Cardiology Laboratory (PCL) at the Broad Institute of MIT and Harvard. His work focuses on the design, implementation, and execution of strategies to develop therapeutics for cardiac diseases in early development. Srivastava has a keen interest in genetic cardiac disorders and mitochondrial metabolism.
 
Prior to Joining Bayer, Srivastava was a postdoctoral researcher in the respiratory department at Novartis Institutes for Biomedical Research, focusing on the contribution of mitochondrial dysfunction in respiratory disorders. During his time at Novartis, he gained experience in target identification and validation campaigns, and drug discovery.
 
Srivastava received his Ph.D. in cardiovascular physiology from King’s College London, where he studied the role of Nrf2 for protection of the neurovascular unit following cerebral ischemia. Srivastava also completed postdoctoral research at King’s College London, where he studied anti-oxidative therapeutic strategies for cardiovascular diseases and examined the use of positron emission tomography (PET) tracers to visualize oxidative stress following myocardial infarction.